Company Overview and News

1
3 Things In Biotech You Should Learn Today: September 20, 2017

2017-09-20 seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Upvote Downvote

 
Why Merrimack Pharmaceuticals Stock Is Tanking Today

2017-05-31 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
Upvote Downvote

 
Geron's Guiding Light

2017-04-06 seekingalpha
Geron's story during Scarlett's tenure is one of steady progress, not in share price, but in its business operations; Scarlett achieves his greatest coup.
Upvote Downvote

 
The U.S.A. and China Start Talking: Global Week Ahead

2017-04-03 zacks
???The U.S. Institute for Supply Management (ISM) manufacturing Purchasing Managers Index (PMI) is on tap. Closely tracked ISM data will get trader’s attention. A U.S. output expansion has been taking off since last fall. The recovery began well before the U.S. election -- as equity markets and the economy rebounded from a medley of challenges that reached a nadir early in 2016. But, where are we now? Europe’s manufacturing PMI data, also out on Monday, should set a positive tone for equity markets there.
Upvote Downvote

 
FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug

2017-02-28 channelnewsasia
REUTERS: The U.S. Food and Drug Administration said on Tuesday it had approved Lexicon Pharmaceuticals Inc's oral drug to treat carcinoid syndrome diarrhea, a condition that develops in patients with gastrointestinal tumors.
Upvote Downvote

 
Sanofi Nears Agreement to Sell Some Over-the-Counter Drugs to Ipsen: Source - Bloomberg

2017-02-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Sanofi nears deal to sell some over-the-counter drugs to Ipsen - Bloomberg

2017-02-13 reuters
Drugmaker Sanofi (SASY.PA) is close to selling some over-the-counter products to Ipsen SA (IPN.PA), in a deal that could be valued at nearly 100 million euros ($106.18 million), Bloomberg reported.
Upvote Downvote

 
Nikkei at more than 1-month highs as yen weakens on Trump relief

2017-02-13 reuters
TOKYO Feb 13 Japan's Nikkei share average probed more than one-month highs on Monday, cheered by Wall Street breaking records, a weaker yen and relief that talks between U.S. President Donald Trump and Japan's Prime Minister Shinzo Abe yielded no negative surprises.
Upvote Downvote

 
US issuers rush to sell Formosa bonds before rule change

2017-02-13 reuters
SINGAPORE, Feb 13 (IFR) - Three US blue chips headed to Taiwan's Formosa bond market last week in a rush to lock in flexible funding ahead of changes in local regulations and a potential shake-up in US tax rules.
Upvote Downvote

 
Morning News Call - India, February 13

2017-02-13 reuters
TOKYO, Feb 13 Japan's Nikkei share average probed more than one-month highs on Monday, cheered by Wall Street breaking records, a weaker yen and relief that talks between U.S. President Donald Trump and Japan's Prime Minister Shinzo Abe yielded no negative surprises.
Upvote Downvote

 
MIDEAST STOCKS - Factors to watch - Feb 13

2017-02-13 reuters
DUBAI Feb 13 Here are some factors that may affect Middle East stock markets on Monday. Reuters has not verified the press reports and does not vouch for their accuracy.
Upvote Downvote

 
Sanofi nears deal to sell some over-the-counter drugs to Ipsen: Bloomberg

2017-02-13 channelnewsasia
REUTERS: Drugmaker Sanofi is close to selling some over-the-counter products to Ipsen SA , in a deal that could be valued at nearly 100 million euros (US$106.18 million), Bloomberg reported.
Upvote Downvote

 
Is Merrimack Pharmaceuticals Worth Stashing in Portfolios?

2017-02-12 fool
Biotech investors can make big profits when clinical-stage biotech stocks net wins from the U.S. Food and Drug Administration, but in the case of Merrimack Pharmaceuticals (NASDAQ:MACK), its stock has been a bust since the FDA approved its pancreatic cancer drug, Onivyde, back in 2015.
Upvote Downvote

 
Latest Reports on Diffusion and Merrimack as Drug Stocks are Hit by President Trump's Comments

2017-01-12 accesswire
NEW YORK, NY / ACCESSWIRE / January 12, 2017 / Biotech and Healthcare stocks were slammed Wednesday as President Donald Trump made some critical remarks against the industries at his first news conference since the election. The 5 largest losers in the S&P 500 Index were all pharmaceutical or biotech companies in early trading Wednesday. The iShares NASDAQ Biotechnology Index ETF fell by as much as 4 percent before settling to close down 2.
Upvote Downvote

 
Why Williams Companies Inc (WMB), Fitbit Inc (FIT) and Merrimack Pharmaceuticals Inc (MACK) Are 3 of Today’s Worst Stocks

2017-01-10 investorplace
Although stocks got Tuesday started on a bullish foot, the optimism faded by midday. A measurable gain that pushed the S&P 500 within sight of a new record high withered away as the day wore on, and the index’s close of 2,268.95 was essentially even with Monday’s last trade.
Upvote Downvote

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...